Transpact Enterprises Ltd Stock Price Today (NSE: TRANSPACT)

Transpact Enterprises Ltd

200.35+0.00 (+0.00%)
Market Closed

Fundamental Score

...

Transpact Enterprises Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Transpact Enterprises Ltd share price today is 200.35, up +0.00% on NSE/BSE as of 17 June 2026. Transpact Enterprises Ltd (TRANSPACT) is a Small-cap company in the Medical Equipment & Supplies sector with a market capitalisation of 6.38 (Cr). The 52-week high for TRANSPACT share price is 299.40 and the 52-week low is 119.55. At a P/E ratio of 63.80x, TRANSPACT is currently trading above its industry average P/E of 47.87x. The company has a Return on Equity (ROE) of 2.22% and a debt-to-equity ratio of 0.12.

Transpact Enterprises Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
200.35
Low
200.00
Volume
0
Change
+0.00%

Transpact Enterprises Ltd share price chart: 0.00% return over the past month. 52-week high ₹299.40, 52-week low ₹119.55.

Transpact Enterprises Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
200.00200.00200.00200.000.00 (Cr)
200.00200.00200.00200.000.00 (Cr)
200.00200.00200.00200.000.00 (Cr)
200.00200.00200.00200.000.00 (Cr)
200.00200.00200.00200.000.00 (Cr)
200.00200.00200.00200.000.00 (Cr)
200.00200.00200.00200.000.00 (Cr)
200.00200.00200.00200.000.00 (Cr)
200.00200.00200.00200.000.00 (Cr)
200.00200.00200.00200.000.00 (Cr)

Transpact Enterprises Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
200.00200.00200.00200.00+0.00%
200.00200.00200.00200.00+0.00%
196.40200.00196.40200.00+1.83%
166.00234.90166.00206.70+24.52%
135.00174.75130.20174.70+29.41%
142.50144.45130.40130.40-8.49%
165.00165.00119.55137.90-16.42%
224.30224.30160.00165.00-26.44%
236.10236.10236.10236.10+0.00%
178.60224.90178.60224.90+25.92%
222.65222.65140.55170.10-23.60%
293.80297.50227.15227.15-22.69%

AI Research Briefing

Powered by Gemini · 2026-04-20

Micro-cap MedTech hopeful with terrible financials and a consulting past; sector tailwinds won't save this.

Research Confidence
6.0/10Moderate
MICRO-CAP DARK HORSE1M: -30.11%Expensive at P/E 63.8x vs industry 47.87x.

WHAT'S HAPPENING NOW (last 2-4 weeks)

No major catalysts found after live search. Transpact Enterprises primarily releases compliance certificates. Last price I see is on April 17, 2026.

CORE STORY (THE REAL GAME)

Why Now
  • MedTech sector growth potential
  • Government support for domestic manufacturing
  • Potential turnaround story
Potential Catalysts
  • Successful product launch
  • Large order win
  • Acquisition by a larger player
Key Risks
  • Micro-cap liquidity risk
  • Negative Free Cash Flow
  • Tiny promoter holding with significant decrease
  • stretched valuation
  • Negative OPM
Institutional Activity

Promoter holding decreased significantly to 0.13%.

Macro Context

India's medical device sector is projected to grow significantly.

Cash Flow Quality

Poor, Free Cash Flow 5Y: ₹-0.88 Cr

3–6 Month Outlook

Hoping to ride the MedTech wave, needs to execute flawlessly. Unlikely.

Primary Thesis Risk

Failure to transition to a profitable MedTech business.

For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.

Returns & Performance

Poor

Return on Equity (ROE)

2.22%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

0.00%

Returns generated on total capital deployed

Poor

Oper. Profit Margin (5Y Avg)

-39.06%

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Transpact Enterprises Ltd Valuation Check

Poor

Price to Earnings (P/E)

63.80x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

47.87x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Poor

Promoter Holding

0.13%

% shares held by company founders/management

Poor

FII Holding

0.00%

% shares held by foreign institutional investors

Poor

DII Holding

0.00%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Excellent

Profit Growth (Quarterly YoY)

200.00%

Net profit growth vs same quarter last year

Revenue Growth (Quarterly YoY)

N/A

Revenue growth vs same quarter last year

Revenue Growth (5-Year CAGR)

N/A

Compounded annual revenue growth over 5 years

Excellent

EPS Growth (5-Year CAGR)

15.14%

Earnings per share growth over 5 years

Excellent

Net Profit Growth (5-Year CAGR)

15.14%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.12x

Total debt ÷ equity. Below 0.5 = financially healthy

Interest Coverage Ratio

N/A

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

-0.88 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Transpact Enterprises Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of TRANSPACT across key market metrics for learning purposes.

Positive Indicators

5 factors identified

Robust Profit Growth (200.00%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture.

Excellent EPS Growth (15.14% CAGR)

Observation: Outstanding 5-year earnings per share compound growth.

Analysis: EPS CAGR >15% indicates strong wealth creation potential.

Strong Profit Growth Track Record (15.14% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model.

Conservative Debt Levels (D/E: 0.12)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

7 factors identified

Below-Average Return on Equity (2.22%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Suboptimal ROCE (0.00%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.

Margin Pressure Concerns (-39.06%)

Observation: Operating margins are below industry standards.

Analysis: OPM <5% may indicate pricing pressures or cost management challenges.

Premium Valuation Risk (P/E: 63.80x)

Observation: High valuation multiples may limit upside potential.

Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.

Negative Free Cash Flow (₹-0.88 Cr over 5Y)

Observation: Cash outflows exceed inflows.

Analysis: Negative FCF requires analysis of capital expenditure cycle.

Low Promoter Commitment (0.13%)

Observation: Reduced promoter stake may indicate limited confidence.

Analysis: Low promoter holding may raise questions about management commitment.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Transpact Enterprises Ltd vs Medical Equipment & Supplies Peers

Peer Comparison - Medical Equipment & Supplies

Compare Transpact Enterprises Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
1.5/100
200
₹6.38
63.8
Average
2.22%
Poor
0.00%
Poor
0.1
Excellent
15.14%
Excellent
0.00%
60.7/100
1330
₹19506.20
53.9
Average
15.77%
Good
20.08%
Excellent
0.1
Excellent
28.38%
Excellent
19.44%
Excellent
0.18%
31.7/100
37
₹3162.93
157.5
Average
0.70%
Poor
1.08%
Poor
0.1
Excellent
0.01%
68.7/100
243
₹1488.44
57.8
Average
21.88%
Excellent
19.20%
Good
0.0
Excellent
57.51%
Excellent
9.81%
Good
0.00%
42.1/100
497
₹1363.11
50.1
Average
30.08%
Excellent
31.14%
Excellent
0.6
Good
0.00%
13.8/100
215
₹1224.98
59.6
Average
4.75%
Poor
6.91%
Poor
0.6
Good
0.00%
60.3/100
173
₹633.93
25.8
Average
36.78%
Excellent
31.12%
Excellent
0.5
Good
90.06%
Excellent
61.82%
Excellent
0.00%
68.5/100
408
₹521.17
26.2
Average
18.74%
Good
25.25%
Excellent
0.0
Excellent
29.49%
Excellent
22.80%
Excellent
0.23%
61.2/100
413
₹354.57
34.2
Average
13.58%
Average
16.35%
Good
0.4
Excellent
74.11%
Excellent
13.69%
Good
0.00%
47.7/100
187
₹294.37
32.7
Average
13.56%
Average
18.45%
Good
0.0
Excellent
0.00%
Nureca Ltd...
NURECA543264
36/100
272
₹292.61
71.2
Average
-1.12%
Poor
-0.90%
Poor
0.0
Excellent
1.98%
Average
0.00%

Transpact Enterprises Ltd Quarterly Performance

Latest quarterly metrics for TRANSPACT — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

N/A

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

200.00%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

N/A

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

15.14%

Compounded annual net profit growth over 5 years

Transpact Enterprises Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for TRANSPACT — calculated from daily price history

100RSI 14
Overbought — RSI 100

Momentum is strong — price may be stretched. Watch for pullbacks.

SMA 50
200
▲ Price above SMA 50 — Short-term bullish

Technical indicators are for educational purposes only. Not investment advice.

Transpact Enterprises Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Transpact Enterprises Ltd (TRANSPACT) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Transpact Enterprises Ltd

About TRANSPACT (Transpact Enterprises Ltd)

Transpact Enterprises Ltd. is a pioneering force in the medical equipment and supplies sector, dedicated to delivering innovative and reliable solutions that empower healthcare pro...fessionals and enhance patient outcomes. We specialize in the sourcing, distribution, and maintenance of a comprehensive range of cutting-edge medical devices, diagnostic tools, and essential supplies. Our portfolio spans across diverse medical disciplines, from advanced imaging systems and surgical instruments to patient monitoring devices and everyday consumables. We are committed to providing quality products that conform to strict quality control standards, ensuring optimal performance and safety in critical healthcare settings. Transpact works closely with its client base to offer tailored support and solutions. At Transpact Enterprises, we understand the ever-evolving needs of the healthcare industry. That's why we prioritize continuous improvement and innovation to stay at the forefront of technological advancements. Our team of experienced professionals is passionate about fostering strong partnerships with healthcare providers, offering expert guidance and technical assistance to optimize the utilization of our products. Beyond the provision of high-quality medical equipment, we offer comprehensive maintenance and repair services, ensuring the longevity and optimal functionality of the devices we supply. We strive to be more than just a supplier, we provide long lasting solutions and services. Our mission at Transpact is to contribute to a healthier future by equipping healthcare professionals with the tools they need to provide exceptional care. We operate with integrity, transparency, and a deep sense of responsibility, adhering to the highest ethical standards in all our business practices. Our commitment to excellence extends beyond the products we offer to the relationships we build with our clients, partners, and the communities we serve. Transpact Enterprises Ltd. envisions a world where innovative medical technologies are readily available to improve the lives of patients and empower healthcare providers to deliver the best possible care.

Company Details

Symbol:TRANSPACT
Industry:Medical Equipment & Supplies
Sector:Medical Equipment & Supplies

Key Leadership

Mr. Raman Neresh kumar Talwar
Chairperson & MD
Ms. Amrita Gupta
Company Secretary & Compliance Officer
Prof. Anis Ahmed Choudhery
Co-Founder & Chief Product Officer

TRANSPACT Share Price: Frequently Asked Questions

What is the current share price of Transpact Enterprises Ltd?

Transpact Enterprises Ltd (TRANSPACT) trades at ₹200.35 on NSE and BSE. Market cap ₹6.38 (Cr). Educational data only.

What is the P/E ratio of Transpact Enterprises Ltd?

Transpact Enterprises Ltd has a P/E of 63.80x vs industry average 47.87x.

What is the Bull Run score for Transpact Enterprises Ltd?

Transpact Enterprises Ltd has a Bull Run score of 1.5/100 based on 25+ financial parameters.

Does Transpact Enterprises Ltd pay dividends?

Transpact Enterprises Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Transpact Enterprises Ltd?

Transpact Enterprises Ltd has ROE of 2.22%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Transpact Enterprises Ltd?

Transpact Enterprises Ltd has debt-to-equity of 0.12.

Is Transpact Enterprises Ltd a good investment?

Bull Run gives Transpact Enterprises Ltd a score of 1.5/100. This is not investment advice — consult a SEBI-registered advisor.